Intech Investment Management LLC Invests $229,000 in AnaptysBio, Inc. (NASDAQ:ANAB)

Intech Investment Management LLC acquired a new stake in AnaptysBio, Inc. (NASDAQ:ANAB) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 6,823 shares of the biotechnology company’s stock, valued at approximately $229,000.

Several other institutional investors have also added to or reduced their stakes in ANAB. Frazier Life Sciences Management L.P. raised its stake in AnaptysBio by 140.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after acquiring an additional 1,265,891 shares in the last quarter. Jennison Associates LLC acquired a new position in AnaptysBio during the 3rd quarter worth approximately $8,874,000. Victory Capital Management Inc. lifted its stake in AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after purchasing an additional 206,750 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in AnaptysBio by 55.1% in the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after buying an additional 168,813 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of AnaptysBio during the second quarter worth $1,360,000.

Insider Transactions at AnaptysBio

In related news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. This trade represents a 8.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Dennis Mulroy sold 12,220 shares of AnaptysBio stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the sale, the chief financial officer now owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. The trade was a 72.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,440 shares of company stock worth $892,936 over the last quarter. Corporate insiders own 33.70% of the company’s stock.

AnaptysBio Stock Down 1.7 %

ANAB opened at $23.66 on Friday. The company’s 50-day moving average price is $27.31 and its two-hundred day moving average price is $29.63. AnaptysBio, Inc. has a twelve month low of $15.78 and a twelve month high of $41.31. The stock has a market cap of $719.97 million, a price-to-earnings ratio of -3.89 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 million. As a group, sell-side analysts anticipate that AnaptysBio, Inc. will post -6.02 earnings per share for the current year.

Wall Street Analyst Weigh In

ANAB has been the subject of several research reports. Wedbush reiterated an “outperform” rating and issued a $42.00 target price on shares of AnaptysBio in a research report on Thursday, November 14th. BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday. JPMorgan Chase & Co. cut their target price on shares of AnaptysBio from $75.00 to $66.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. Guggenheim upped their price target on shares of AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, Truist Financial lifted their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $54.64.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.